Business Description
Charles River Laboratories International Inc
NAICS : 541714
SIC : 8732
ISIN : US1598641074
Total Employee Number:
19,700Compare
Compare
Traded in other countries / regions
CRL.USARV6.Germany1CRL.ItalyCRL.Mexico Index Membership
S&P 500Russell 1000Russell 3000 IPO Date
2000-06-23Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.06 | |||||
Equity-to-Asset | 0.38 | |||||
Debt-to-Equity | 1.04 | |||||
Debt-to-EBITDA | 10.52 | |||||
Interest Coverage | 4.22 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.18 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.5 | |||||
3-Year EBITDA Growth Rate | -24.5 | |||||
3-Year EPS without NRI Growth Rate | -2.6 | |||||
3-Year FCF Growth Rate | 22.1 | |||||
3-Year Book Growth Rate | 3.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 9.55 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 91.4 | |||||
9-Day RSI | 83.69 | |||||
14-Day RSI | 77.16 | |||||
3-1 Month Momentum % | 4.76 | |||||
6-1 Month Momentum % | -9.41 | |||||
12-1 Month Momentum % | 19.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.36 | |||||
Quick Ratio | 1.03 | |||||
Cash Ratio | 0.18 | |||||
Days Inventory | 40.99 | |||||
Days Sales Outstanding | 48.78 | |||||
Days Payable | 20.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.1 | |||||
Shareholder Yield % | 2.6 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 32.29 | |||||
Operating Margin % | 11.08 | |||||
Net Margin % | -4.59 | |||||
EBITDA Margin % | 7.22 | |||||
FCF Margin % | 9.72 | |||||
OCF Margin % | 15.07 | |||||
ROE % | -5.75 | |||||
ROA % | -2.46 | |||||
ROIC % | 6.49 | |||||
3-Year ROIIC % | 25.79 | |||||
ROC (Joel Greenblatt) % | -3.02 | |||||
ROCE % | -0.93 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 20.42 | |||||
PE Ratio without NRI | 22.68 | |||||
Shiller PE Ratio | 41.16 | |||||
PS Ratio | 2.75 | |||||
PB Ratio | 3.81 | |||||
Price-to-Free-Cash-Flow | 28.57 | |||||
Price-to-Operating-Cash-Flow | 18.41 | |||||
EV-to-EBIT | -232.4 | |||||
EV-to-Forward-EBIT | 27.91 | |||||
EV-to-EBITDA | 47.62 | |||||
EV-to-Forward-EBITDA | 17.42 | |||||
EV-to-Revenue | 3.44 | |||||
EV-to-Forward-Revenue | 3.55 | |||||
EV-to-FCF | 35.36 | |||||
Price-to-GF-Value | 1.16 | |||||
Price-to-Projected-FCF | 1.73 | |||||
Price-to-Median-PS-Value | 0.99 | |||||
Earnings Yield (Greenblatt) % | -0.43 | |||||
FCF Yield % | 3.58 | |||||
Forward Rate of Return (Yacktman) % | -9.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:CRL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Charles River Laboratories International Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4,027.044 | ||
| EPS (TTM) ($) | -3.76 | ||
| Beta | 1.5321 | ||
| 3-Year Sharpe Ratio | 0.03 | ||
| 3-Year Sortino Ratio | 0.04 | ||
| Volatility % | 32.02 | ||
| 14-Day RSI | 77.16 | ||
| 14-Day ATR ($) | 8.503593 | ||
| 20-Day SMA ($) | 190.345 | ||
| 12-1 Month Momentum % | 19.1 | ||
| 52-Week Range ($) | 144.26 - 228.88 | ||
| Shares Outstanding (Mil) | 48.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Charles River Laboratories International Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Charles River Laboratories International Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 09:00 | In 128 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 127 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 09:00 | In 37 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 36 days | ||
| Jefferies Global Healthcare Conference | 2026-06-03 09:55 | 174.79 (-2.35%) | ||
| William Blair and Jefferies Conferences | 2026-06-02 11:00 | 182.07 (+0.99%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 181.73 (-2.94%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 181.73 (-2.94%) | ||
| General meeting for 2026 | 2026-05-05 08:00 | 172.32 (+4.58%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-10 10:00 | 176.99 (+2.47%) |
Show
Entries
Charles River Laboratories International Inc Frequently Asked Questions
What is Charles River Laboratories International Inc(CRL)'s stock price today?
The current price of CRL is $226.79. The 52 week high of CRL is $228.88 and 52 week low is $144.26.
When is next earnings date of Charles River Laboratories International Inc(CRL)?
The next earnings date of Charles River Laboratories International Inc(CRL) is 2026-08-06 Est..
Does Charles River Laboratories International Inc(CRL) pay dividends? If so, how much?
Charles River Laboratories International Inc(CRL) does not pay dividend.
Guru Commentaries on NYSE:CRL
No articles.
Press Release
Articles on Charles River Laboratories International Inc
No articles.
Headlines
See More- 1
Jun 17, 2026
Charles River upgraded, IQVIA downgraded as Morgan Stanley revisits CRO coverage
Seeking Alpha • 9:14am
This Charles River Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Benzinga • 8:08am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers